Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Westpac Banking Corp

Westpac Banking Corp increased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 21.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,132 shares of the company’s stock after purchasing an additional 921 shares during the quarter. Westpac Banking Corp’s holdings in Moderna were worth $213,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of MRNA. State Street Corp increased its position in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC grew its stake in Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock valued at $300,219,000 after acquiring an additional 171,774 shares during the period. Wellington Management Group LLP increased its holdings in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after acquiring an additional 906,114 shares in the last quarter. Norges Bank acquired a new position in Moderna during the fourth quarter worth $163,833,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Moderna by 9.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock valued at $97,472,000 after purchasing an additional 211,426 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of research reports. Berenberg Bank boosted their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Leerink Partners reduced their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. JPMorgan Chase & Co. lowered their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Friday, March 21st. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $59.00.

Moderna Trading Down 2.4 %

Shares of MRNA opened at $25.11 on Friday. The company’s 50-day moving average price is $33.55 and its 200 day moving average price is $43.01. Moderna, Inc. has a 12-month low of $23.76 and a 12-month high of $170.47. The firm has a market cap of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.